ConductScience.org, home

Paper41940985

Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.

Bruzzese A and 11 others. Ann Hematol, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials. Papers, record 41940985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41940985

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
PubMed
Journal
Ann Hematol
PubMed
Year
2026
PubMed
Publication types
Network Meta-Analysis, Journal Article, Comparative Study
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bruzzese AAntonella
2Lofaro DDanilo
3Martino EAEnrica Antonia
4Mendicino FFrancesco
5Labanca CCaterina
6Caserta SSantino
7Lucia EEugenio
8Olivito VVirginia
9Amodio NNicola
10Morabito FFortunato
11Vigna EErnesto
12Gentile MMassimo

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
fms-Like Tyrosine Kinase 3Major topic
Leukemia, Myeloid, AcuteMajor topic
MutationMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Randomized Controlled Trials as Topic
Bayes Theorem
Phenylurea Compounds
Decitabine
Treatment Outcome
Sorafenib
Gemtuzumab
Staurosporine
Protein Kinase Inhibitors
Benzothiazoles
Cytarabine
Daunorubicin

Source PubMed

Download CSV of topics

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140097915A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.Cancer2025https://conductscience.org/library/papers/40097915PubMed
235797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022https://conductscience.org/library/papers/35797463PubMed
326549589
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol2015https://conductscience.org/library/papers/26549589PubMed
437647654Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.Blood2023https://conductscience.org/library/papers/37647654PubMed
538324741Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.J Clin Oncol2024https://conductscience.org/library/papers/38324741PubMed
633563904Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J2021https://conductscience.org/library/papers/33563904PubMed
740932876V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.Blood Neoplasia2025https://conductscience.org/library/papers/40932876PubMed
839067406The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis.Leuk Res2024https://conductscience.org/library/papers/39067406PubMed
937604981Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.Leukemia2023https://conductscience.org/library/papers/37604981PubMed
1031462531RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ2019https://conductscience.org/library/papers/31462531PubMed
1115959528Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.Leukemia2005https://conductscience.org/library/papers/15959528PubMed
1222482940Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.Lancet2012https://conductscience.org/library/papers/22482940PubMed
1330076173Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.Haematologica2019https://conductscience.org/library/papers/30076173PubMed
1438717861Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.Blood2024https://conductscience.org/library/papers/38717861PubMed
1532241850
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica2020https://conductscience.org/library/papers/32241850PubMed
1636497281Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.Cancers (Basel)2022https://conductscience.org/library/papers/36497281PubMed
1735732831The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.Leukemia2022https://conductscience.org/library/papers/35732831PubMed
1837116523
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet2023https://conductscience.org/library/papers/37116523PubMed
1938215358
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
J Clin Oncol2024https://conductscience.org/library/papers/38215358PubMed
2036815379Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience.Haematologica2023https://conductscience.org/library/papers/36815379PubMed

See all 33 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42452347Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.J Clin Med2026https://conductscience.org/library/papers/42452347

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41940985

GET https://conductscience.org/api/papers/v1/41940985/references?page=2